Granted Patent
B2
US 12,653,824 · App. 19/169,836 · Granted Jun 16, 2026
Compositions and use of varenicline for treating dry eye
Inventors:
Douglas Michael Ackermann, Jr. (Reno, NV); James Loudin (Houston, TX); Kenneth J. Mandell (Lexington, MA)
Assignee:
Oyster Point Pharma, Inc.
A61K31/4995A61K9/0043A61K9/0048A61K9/007A61K9/08A61K31/439A61K31/4427A61K31/4439A61K31/4985A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Described herein are methods and pharmaceutical formulations for treating dry eye disease.
Claims (13)
1 . A nasal spray bottle containing an aqueous liquid pharmaceutical formulation for administration into a nasal cavity of a human, the formulation comprising a solution of varenicline or a pharmaceutically acceptable varenicline salt and one or more pharmaceutically acceptable inactive ingredients, wherein varenicline is the single therapeutic agent in the formulation, the concentration of varenicline in the formulation is between about 0.1 mg/mL and about 2 mg/mL, and one spray of the formulation from the bottle contains between 10 micrograms and 50 micrograms of varenicline.
2 . The nasal spray bottle of claim 1 , wherein the formulation comprises a buffer selected from a phosphate buffer and a phosphate-citrate buffer.
3 . The nasal spray bottle of claim 2 , wherein the formulation comprises a phosphate buffer, wherein the pH of the phosphate buffer is around 7.0.
4 . The nasal spray bottle of claim 2 , wherein the formulation comprises a phosphate-citrate buffer, wherein the pH of the phosphate-citrate buffer is from around 5.0 to around 6.0.
5 . The nasal spray bottle of claim 1 , wherein the formulation is preservative-free.
6 . The nasal spray bottle of claim 5 , wherein the formulation comprises a salt for regulating osmotic pressure.
7 . The nasal spray bottle of claim 1 , wherein the volume of one spray from the bottle is 50 microliters.
8 . The nasal spray bottle of claim 7 , wherein the formulation comprises a buffer selected from a phosphate buffer and a phosphate-citrate buffer.
9 . The nasal spray bottle of claim 8 , wherein the formulation comprises a phosphate buffer and the pH of the phosphate buffer is around 7.0.
10 . The nasal spray bottle of claim 8 , wherein the formulation comprises a phosphate-citrate buffer and the pH of the phosphate-citrate buffer is from around 5.0 to around 6.0.
11 . The nasal spray bottle of claim 7 , wherein the formulation is preservative-free.
12 . The nasal spray bottle of claim 11 , wherein the formulation comprises a salt for regulating osmotic pressure.
13 . The nasal spray bottle of claim 8 , for local administration into the nasal cavity of the human.
Continuity (8)
Provisional Application
62100844
· Jan 7, 2015
Provisional Application
62066280
· Oct 20, 2014
References Cited (167)
US 6277855B1
· Yerxa
· 2001
[cited by applicant]
US 8273731B2
· Heldman
· 2012
[cited by applicant]
US 8273780B2
· Hutchinson et al.
· 2012
[cited by applicant]
US 8440235B2
· Tseng et al.
· 2013
[cited by applicant]
US 9145396B2
· Akireddy et al.
· 2015
[cited by applicant]
US 9504644B2
· Ackermann et al.
· 2016
[cited by applicant]
US 9504645B2
· Ackermann et al.
· 2016
[cited by applicant]
US 9532944B2
· Ackermann et al.
· 2017
[cited by applicant]
US 9597284B2
· Ackermann et al.
· 2017
[cited by applicant]
US 20060084656A1
· Ziegler et al.
· 2006
[cited by applicant]
US 20070093420A1
· Yeomans et al.
· 2007
[cited by applicant]
US 20080261890A1
· Ousler et al.
· 2008
[cited by applicant]
US 20090093446A1
· Bernstein
· 2009
[cited by applicant]
US 20090215787A1
· Huang et al.
· 2009
[cited by applicant]
US 20110086086A1
· Johnson et al.
· 2011
[cited by applicant]
US 20110263629A1
· Strachan et al.
· 2011
[cited by applicant]
US 20110274628A1
· Borschke
· 2011
[cited by applicant]
US 20140357971A1
· Eilat et al.
· 2014
[cited by applicant]
US 20200345734A1
· Ackermann et al.
· 2020
[cited by applicant]
US 20210379066A1
· Nau et al.
· 2021
[cited by applicant]
US 20240173318A1
· Ackermann, Jr. et al.
· 2024
[cited by applicant]
US 20240173381A1
· Kosai et al.
· 2024
[cited by applicant]
US 20250235449A1
· Ackermann, Jr. et al.
· 2025
[cited by applicant]
CA 2583101A1
· 2006
[cited by applicant]
EP 1214062B1
· 2003
[cited by applicant]
JP 2003531168A
· 2003
[cited by applicant]
JP 2011504490A
· 2011
[cited by applicant]
JP 2012510471A
· 2012
[cited by applicant]
JP 2017531044A
· 2017
[cited by applicant]
WO 2001080844A2
· 2001
[cited by applicant]
WO 2003005998A2
· 2003
[cited by applicant]
WO 2003045394A1
· 2003
[cited by applicant]
WO 2004039366A1
· 2004
[cited by applicant]
WO 2006100075A2
· 2006
[cited by applicant]
WO 2008057938A1
· 2008
[cited by applicant]
WO 2009069126A1
· 2009
[cited by applicant]
WO 2009111550A1
· 2009
[cited by applicant]
WO 2010028011A1
· 2010
[cited by applicant]
WO 2010028033A1
· 2010
[cited by applicant]
WO 2010065443A1
· 2010
[cited by applicant]
WO 2013057687A2
· 2013
[cited by applicant]
WO 2016064759A1
· 2013
[cited by applicant]
WO 2014152385A2
· 2014
[cited by applicant]
WO 2017177024A1
· 2017
[cited by applicant]
WO 2020014232A1
· 2020
[cited by applicant]
WO 2020014217A1
· 2020
[cited by applicant]
Nicotrol NS (nicotine nasal spray) FDA label (approved Mar. 22, 1996, label version from 2010 or earlier used here) (Year: 2010).
[cited by examiner]
Washington et al. (Determination of baseline human nasal pH and the effect of intranasally administered buffers, International Journal of Pharmaceutics, 198(2), 139-146) (Year: 2000).
[cited by examiner]
Setala, N. , “Interrelationship Between Dry Eye Syndrome and Tear Fluid Phospholipid Transfer Protein” Academic Dissertation, Department or Ophthalmology, University of Helsinki, 2011, pp. 13, 29-30.
[cited by applicant]
Bitter, C. et al., “Nasal Drug Delivery in Humans in Topical Applications and the Mucosa”, Current Problems in Dermatology, Feb. 10, 2011, vol. 40, pp. 20-35.
[cited by applicant]
Herman, A. et al., “Cognitive Effects of Nicotine: Genetic Moderators”, Addiction Biology, Jul. 2010, pp. 250-265, vol. 15(3).
[cited by applicant]
Karnati, Roy et al., “Lacritin and the tear proteome as natural replacement therapy for dry eye”, Experimental Eye Research, Dec. 2013, pp. 39-52, vol. 117.
[cited by applicant]
Mihalak, K. et al., “Varenicline is a partial agonist at α482 and a full agonist at α7 neuronal nicotinic receptors”, Molecular Pharmacology, Jun. 9, 2008, pp. 801-805, vol. 70.
[cited by applicant]
Mohanasundaram, U. et al., “Smoking Cessation Therapy with Varenicline”, International Journal of Chronic Obstruction Pulmonary Disease, Jun. 6, 2008, pp. 239-251, vol. 3(2).
[cited by applicant]
Patel, PB et al., “Ophthalmic Drug Delivery System: Challenges and Approaches”, Systemic Review in Pharmacy, Jan. 2010, 1(2) p. 113.
[cited by applicant]
Robson, N., “Nicotine-replacement therapy: a proven treatment for smoking cessation”, South African Family Practice, 2010, vol. 52, Issue 4, pp. 298-303.
[cited by applicant]
Winfield, AJ et al., “A Study of the Causes of Non-compliance by Patients Prescribed Eyedrops”, British Journal of Ophthalmology, Aug. 1990, pp. 477-480. vol. 74.
[cited by applicant]
EPO, Interlocutory Decision in Opposition Proceedings, dated Feb. 23, 2023, in connection with European Patent 3 209 295 (European Pat. App. No. 15852340. 7).
[cited by applicant]
Declaration of Prof. Daniel Bertrand, dated Jan. 6, 2023, submitted to European Patent Office in connection with EP 3 209 295 (European Pat. App. No. 15 852 340. 7).
[cited by applicant]
Iturriaga-Vasquez, P. et al., “Pharmacological Research” , 2015, pp. 9-17, vol. 101.
[cited by applicant]
U.S. FDA Label for New Drug Application (NOA) 021928, CHANTIX (varenicline) tablets, for oral use (Feb. 2019).
[cited by applicant]
Complaint filed Jul. 19, 2023 with the U.S. District Court for the District of New Jersey on behalf of Oyster Point Pharma, Inc.
[cited by applicant]
Answer filed Jul. 31, 2023 on behalf of Apotex Inc. with the U.S District Court for the District of New Jersey subsequent to the aforementioned Complaint.
[cited by applicant]
Notice of Certification Under 21 U.S.C. § 3550(J)(2)(B) § (505)(J)(2)(B) of the Federal Food, Drug, and Cosmetic Act) and 21 C.F.R. §314.95, dated Jun. 5, 2023, from Apotex, Inc (redacted).
[cited by applicant]
United States Patent and Trademark Office, Office Action for U.S. Appl. No. 16/852,225, filed Nov. 17, 2022, 19 pages.
[cited by applicant]
Colligris B., et al., “Recent developments on dry eye disease treatment compounds”, Saudi Journal of Ophthalmology 2014, 28, 19-30.
[cited by applicant]
U. Grau, et al. “Next-generation calcineurin inhibitors for ophthalmic indications”, Expert Opinion on Investigational Drugs 2007, pp. 1525-1540.
[cited by applicant]
United States Patent and Trademark Office, Office Action for U.S. Appl. No. 16/852,225, filed Jun. 6, 2023, 21 pages.
[cited by applicant]
Marrero, MB et al., “An α7 Nicotinic Acetylcholine Receptor-Selective Agonist Reduces Weight Gain and Metabolic Changes in a Mouse Model of Diabetes,” Journal of Pharmacology and Experimental Therapeutics Jan. 2010, 332…
[cited by applicant]
United States Patent and Trademark Office, Notice of Allowance for U.S. Appl. No. 14/887,259, filed Sep. 28, 2016, 8 pages.
[cited by applicant]
Albietz,JM., et al., Dry eye: an update on clinical diagnosis, management and promising new treatments, Clinical and Experimental Optometry, 2001, pp. 4-18, vol. 84(1).
[cited by applicant]
Alimohammadi, H., et al., Evidence for nicotinic acetylcholine receptors on nasal trigeminal nerve endings of the rat, Chem Senses, 2000, pp. 61-66, vol. 25.
[cited by applicant]
Beule, AG., Physiology and pathophysiology of respiratory mucosa of the nose and the paranasal sinuses, GMS Curr Top Otorhinolaryngol Head Neck Surg, 2010, pp. 1-24, vol. 9.
[cited by applicant]
Benitez-Del-Castillo, et al., “Relation between Corneal Innervation with Confocal Microscopy and Corneal Sensitivity with Noncontact Esthesiometry in Patients with Dry Eye”, IOVS, Jan. 2007, 9 pages, vol. 48(1).
[cited by applicant]
Bommer, R., et al. Drug Delivery: Nasal Route, Encyclopedia of Pharmaceutical Technology edited by James Swarbrick, PharmaceuTech, Inc., Pinehurst, North Carolina, USA, Jan. 1, 2007, pp. 1201-1208, vol. 3(1).
[cited by applicant]
Brinton, M., et al., Enhanced Tearing by Electrical Stimulation of the Anterior Ethmoid Nerve, IOVS, Apr. 2017, pp. 2341-2348, vol. 58, No. 4.
[cited by applicant]
Bron, Diagnosis of Dry Eye, Survey of Opthalmology, Mar. 2001, pp. 221-226, vol. 45, Supplement 2.
[cited by applicant]
Bron, et al., Rethinking Dry Eye Disease: a Perspective on Clinical Implications, The Ocular Surface, Apr. 2014, 33 pages, vol. 12(2S).
[cited by applicant]
Chatzidaki, et al., Allosteric modulation of nicotinic acetylcholine receptors, Biochem Pharmacol., Oct. 15, 2015, pp. 408-417, vol. 97, No. 4.
[cited by applicant]
Colligris, et al. Recent developments on dry eye disease treatment compounds, Saudi Journal of Ophthalmology, Jan. 1, 2014, pp. 19-30, vol. 28, No. 1.
[cited by applicant]
Dartt, Neural regulation of lacrimal gland secretory processes: relevance in dry eye diseases, Prog Retin Eye Res., May 2009, pp. 155-177, vol. 28, No. 3. doi: 10. 1016/j.preteyeres.2009.04.003.
[cited by applicant]
Ervin, et al. Punctal occlusion for dry eye syndrome, (Review), Cochrane Database of Systematic Reviews, 2010, pp. 1-25, vol. 9, Art No. CD006775.
[cited by applicant]
European Medicines Agency European Public Assessment Report Summary for the Public: Champix: Varenicline, EMEA/H/C/699, Mar. 1, 2014.
[cited by applicant]
European Patent Office, Extended European Search Report issued by the European Patent Office for Application No. 15852340.7, dated Apr. 24, 2018, 8 pages.
[cited by applicant]
European Patent Office, Extended European Search Report issued by the European Patent Office for Application No. 20212556.3, dated May 28, 2021, 6 pages.
[cited by applicant]
European Patent Office, Notice of Opposition issued by the European Patent Office for Application No. 15852340. 7, dated Sep. 15, 2021, 41 pages.
[cited by applicant]
European Patent Office, International Search Report and Written Opinion issued by the International Searching Authority for Application No. PCT/US2017/026385, dated Jul. 5, 2017, 9 pages.
[cited by applicant]
European Patent Office, International Search Report and Written Opinion issued by the International Searching Authority for Application No. PCT/US2019/041013, dated Oct. 16, 2019, 16 pages.
[cited by applicant]
European Patent Office, International Search Report and Written Opinion issued by the International Searching Authority for Application No. PCT/US2019/040990, dated Oct. 9, 2019, 14 pages.
[cited by applicant]
Federal Drug Administration, Label for FDA approved product TYRVAYA, 11 pages.
[cited by applicant]
Fenster, C. et al., Regulation of α4β2 Nicotinic Receptor Desensitization by Calcium and Protein Kinase C, Mol. Pharmacol., 1999, pp. 432-443, vol. 55(3).
[cited by applicant]
Gupta, A., et al., Nasolacrimal stimulation of aqueous tear production, Cornea, Nov. 1997, pp. 645-648, vol. 16 (6).
[cited by applicant]
Hurst, R. et al., Nicotinic acetylcholine receptors: from basic science to therapeutics, Pharmacol Ther., Jan. 2013, pp. 22-54, vol. 137, No. 1.
[cited by applicant]
Li, N. et al., Comparison of the Schirmer I test with and without topical anesthesia for diagnosing dry eye, Int J Ophthalmol., Aug. 18, 2012, pp. 478-481, vol. 5(4).
[cited by applicant]
Mazzanti, C. , Cyclosporine A inhibits acetylcholinesterase activity in rats experimentally demyelinated with ethidium bromide, Int. J. Devi Neuroscience, 2007, pp. 259-264, vol. 25(4).
[cited by applicant]
Newhouse, P. et al., Therapeutic Applications of Nicotinic Stimulation: Successes, Failures, and Future Prospects, Nicotine & Tobacco Research, Mar. 2019, pp. 345-348, vol. 21(3).
[cited by applicant]
Rollema, H. et al., Pre-clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence, Br J Pharmacol., May…
[cited by applicant]
Rosenblum, M. et al., Mechanisms of human autoimmunity, The Journal of Clinical Investigation, Jun. 2015, pp. 2228-2233, vol. 125(6).
[cited by applicant]
Swarbrick, et al., Encylopedia of Pharmaceutical Technology, Third Ed., 2007, pp. 1201-1208, vol. 1.
[cited by applicant]
Thuerauf, et al., Dose-dependent stereoselective activation of the trigeminal sensory system by nicotine in man, Psychopharmacology, 1999, pp. 236-243, vol. 142.
[cited by applicant]
U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for Industry, Nasal spray and inhalation solution, suspension, and spray drug products—Chem…
[cited by applicant]
United States Patent and Trademark Office, International Search Report and Written Opinion for Application No. PCT/US2015/056273, Jan. 8, 2016, 8 pages.
[cited by applicant]
United States Patent and Trademark Office, Office Action for U.S. Appl. No. 14/887,248, filed Mar. 18, 2016, 13 pages.
[cited by applicant]
United States Patent and Trademark Office, for U.S. Appl. No. 14/887,259, filed Mar. 21, 2016, 14 pages.
[cited by applicant]
United States Patent and Trademark Office, for U.S. Appl. No. 14/887,253, filed Mar. 23, 2016, 14 pages.
[cited by applicant]
United States Patent and Trademark Office, Office Action for U.S. Appl. No. 14/887,243, filed Mar. 24, 2016, 14 pages.
[cited by applicant]
United States Patent and Trademark Office, for U.S. Appl. No. 14/887,248, filed Jun. 28, 2016, 18 pages.
[cited by applicant]
United States Patent and Trademark Office, Office Action for U.S. Appl. No. 16/566,237, filed Dec. 10, 2020, 13 pages.
[cited by applicant]
Baudouin, “The Pathology of Dry Eye,” Survey of Opthalmology, Mar. 2001, vol. 45, Suppl. 2, pp. S211-S220.
[cited by applicant]
United States Patent and Trademark Office, Office Action for U.S. Appl. No. 15/422,382, filed Jul. 13, 2018, 28 pages.
[cited by applicant]
United States Patent and Trademark Office, Final Office Action for U.S. Appl. No. 15/422,382, filed Feb. 25, 2019, 13 pages.
[cited by applicant]
United States Patent and Trademark Office, Office Action for U.S. Appl. No. 16/091,830, filed Feb. 25, 2019, 9 pages.
[cited by applicant]
United States Patent and Trademark Office, Office Action for U.S. Appl. No. 16/091,830, filed Sep. 27, 2019, 9 pages.
[cited by applicant]
United States Patent and Trademark Office, Notice of Allowance for U.S. Appl. No. 16/091,830, filed Jan. 16, 2020, 9 pages.
[cited by applicant]
United States Patent and Trademark Office, Notice of Allowance for U.S. Appl. No. 15/422,382, filed Jun. 12, 2019, 5 pages.
[cited by applicant]
United States Patent and Trademark Office, Final Office Action for U.S. Appl. No. 16/566,237, filed Sep. 13, 2021, 13 pages.
[cited by applicant]
United States Patent and Trademark Office, Notice of Allowance for U.S. Appl. No. 16/566,237, filed Oct. 20, 2021, 12 pages.
[cited by applicant]
United States Patent and Trademark Office, Restriction Requirement for U.S. Appl. No. 16/852,225, filed Mar. 1, 2022, 7 pages.
[cited by applicant]
United States Patent and Trademark Office, Restriction Requirement for U.S. Appl. No. 17/144,548, filed Dec. 10, 2021, 8 pages.
[cited by applicant]
Wang, et al., Selective Activation of (α4)3(β2)2 nAChRs Reduces Ethanol Consumption Without Affecting Ethanol Intoxication, Neuropsychopharmacology, ACNP 55th Annual Meeting, Dec. 7, 2016.
[cited by applicant]
Wang, et al., A Novel α2/α4 Subtype-selective Positive Allosteric Modulator of Nicotinic Acetylcholine Receptors Acting from the C-tail of an a Subunit, J Biol Chem., Nov. 27, 2015, pp. 28834-28846, No. 48, vol. 29.
[cited by applicant]
Hessen et al., “Dry Eye: an Inflammatory Ocular Disease,” Journal of Opthalmic and Vision Research, 2014, pp. 240-250.vol. 9(2).
[cited by applicant]
McKown et al., “Lacritin and other new proteins of the lacrimal functional unit,” Experimental Eye Research, 2009, pp. 848-858, vol. 88.
[cited by applicant]
Pieragostino et al., “Unraveling the molecular repertoire of tears as a source of biomarkers: Beyond ocular disease,” Proteomics Clin. Appl. 2015, pp. 169-186, vol. 9.
[cited by applicant]
Mora, C. et al., How Many Species Are There on Earth and in the Ocean? PloS Biology, 2011, pp. 1-8, vol. 9(8).
[cited by applicant]
Vorobiof, D. A. et al. Nasally Administered Buserelin Inducing Complete Remission of Lung Metastases in Male Breast Cancer, 1987, pp. 688-689.
[cited by applicant]
Pincheira-Donoso, D. et al., Global Taxonomic Diversity of Living Reptiles, PloS One , 2013, pp. 1-10, vol. 8(3).
[cited by applicant]
Neubauer, D., ZolpiMistTM: a New Formulation of Zolpidem tartrate for the short-term treatment of insomnia in the US, Nature & Sci. Sleep, 2012, pp. 79-84, vol. 79.
[cited by applicant]
Storey, E. et al., Use of phenol red thread tests to evaluate tear production in clinically normal Amazon parrots and comparison with Schirmer tear test findings, AVMA 1, 2009, pp. 181-1187, vol. 235(10).
[cited by applicant]
Philip, G. et al., The Human Nasal Response to Capsaicin, J. Allergy Clin. Immunol. 1994, pp. 1035-1045, vol. 94.
[cited by applicant]
Ebbert, J. et al., Varenicline for smoking cessation: efficacy, safety, and treatment recommendations, Patient Preference & Adherence, 2010, pp. 355-362, vol. 4.
[cited by applicant]
Ravva, P. et al. Quantitative Assessment of Exposure-Response Relationships for the Efficacy and Tolerability of Varenicline for Smoking Cessation, Clin. Pharamcol. & Therapeutics 2010, pp. 336-344, vol. 87(3).
[cited by applicant]
Miller, P. et al., Effects of topical administration of 0.5% apraclonidine on intraocular pressure, pupil size, and heart rate in clinically normal cats, AJVR, 1996, pp. 83-86, vol. 57(1).
[cited by applicant]
Toutain, P. et al. Species Differences in Pharmacokinetics and Pharmacodynamics. in: Cunningham, F., Elliott, J., Lees, P. (eds) Comparative and Veterinary Pharmacology. Handbook of Experimental Pharmacology, 2010, vol.…
[cited by applicant]
Anolik, R. , Fluticasone furoate nasal spray: Profile of an enhanced affinity corticosteroid in treatment of seasonal allergic rhinitis, J Asthma and Allergy, 2010, pp. 87-99, vol. 3.
[cited by applicant]
Broide, Ron. et al. Increased Sensitivity to Nicotine-Induced Seizures in Mice Expressing the L250T a7 Nicotinic Acetylcholine Receptor Mutation, Molecular Pharmacology, 2001, pp. 695-705, vol. 61(3).
[cited by applicant]
Rajaei, S. et al. Measurement of Tear Production Using Phenol Red Threat and Standardized Endodontic Absorbent Paper Points in European Pond Turtles (
[cited by applicant]
Crispin, S., Tear-deficient and evaporative dry eye syndromes of the horse, Vet. Ophthalmol., 2000, pp. 87-92, vol. 3.
[cited by applicant]
Baeyens, V. et al., Ocular drug discovery in veterinary medicine, Advanced Drug Delivery Revs., 1997, pp. 335-361, vol. 28.
[cited by applicant]
Biringerova, Z. et al., The effects of nasal irritant induced responses on breathing and cough in anaesthetized and conscious animal models, Respiratory Physio. & Neuro. 2013, pp. 588-593, vol. 189.
[cited by applicant]
Alimohammad, H. et al., Evidence for nicotinic acetylcholine receptors on nasal trigeminal nerve endings of the rat. Chem Senses., Feb. 2000, pp. 61-66, vol. 25(1) .
[cited by applicant]
Liu, L. et al., Neuronal nicotinic acetylcholine receptors in rat trigeminal ganglia. Brain Res., Nov. 2, 1998, pp. 238-245, vol. 809(2).
[cited by applicant]
Ferguson, T. et al., Varenicline Solution Nasal Spray for the Treatment of Dry Eye Disease Following LASIK. Ophthalmol Ther., Jun. 2024, pp. 1693-1701, vol. 13(6).
[cited by applicant]
European Patent Office, Notice of Opposition issued Feb. 12, 2025 by the European Patent Office for EP 3848028, Application No. 20212556.3, 28 pages.
[cited by applicant]
State Intellectual Property Office, May 20, 2025 Notice of Invalidation Request for Chinese Pat. 107106542, filed Apr. 29, 2025.
[cited by applicant]